stockrowBridgeBio Oncology Therapeutics, Inc
BBOT- EPS
- −25.3%
- Free cash flow
- −88.8%
Quarter to June 2026, against a year earlier
Follow BBOT
Alert me
BridgeBio Oncology Therapeutics, Inc (BBOT) Return on invested capital
BridgeBio Oncology Therapeutics, Inc's return on invested capital over the twelve months to 30 June 2026 was −127.7%, down 127.7 percentage points from fiscal 2025 (0.00%). That is below the Biotechnology industry median of 0.00% and below the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | 0.00% | 0.00 |
| FY2024 | 0.00% | — |
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| WHWK Whitehawk Therapeutics, Inc. compare | 0.00% |
| CGEN Compugen Ltd. compare | 0.00% |
| BBOT BridgeBio Oncology Therapeutics, Inc | −127.7% |
| ACOG Alpha Cognition Inc. compare | −144.7% |
| BCYC Bicycle Therapeutics PLC Sponsored ADR compare | −279.8% |
| IVVD Invivyd, Inc. compare | −334.9% |
| UPB Upstream Bio, Inc. compare | −1,100.9% |
| TRDA Entrada Therapeutics, Inc. compare | −2,009.0% |
| MDWD MediWound Ltd. compare | −6,551.8% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)